logo

For the Inventor, By the Inventor

Curacao, Netherlands Antilles

Applied Research Systems Ars Holding N.v.

Calculating rank
USPTO Granted Patents = 156

% Expired Patents = 25.0



Forward Citations = 2,304

Loading Chart...
Loading Chart...

222 inventors (with patents filed for the assignee):

goldMedal Scott C Chappel (12 out of 29 patents)

silverMedal Grenville Arthur Robinson (8 out of 15 patents)

bronzeMedal John W Attridge (7 out of 9 patents)

4.  Sean D McKenna (6 out of 16 patents)

5.  Fabrizio Samaritani (6 out of 16 patents)

6.  Antonio Guarna (6 out of 12 patents)

7.  Mario Serio (6 out of 6 patents)

8.  Matthias Schwarz (5 out of 35 patents)

9.  Frederic Triebel (5 out of 26 patents)

10.  Anna Quattropani (5 out of 58 patents)

11.  Mark Tepper (5 out of 14 patents)

12.  Adulla P Reddy (5 out of 8 patents)

13.  Francesco Borrelli (5 out of 7 patents)

14.  Ottaviano Serlupi-Crescenzi (5 out of 5 patents)

15.  Edward G Bernstine (5 out of 9 patents)


Core Competencies:
Prostaglandin Agonists
Ovulation Induction
Glycoproteins
PEG Conjugates
Recombinant Proteins
JNK Modulators
Neurodegenerative Diseases
Chemokine Antagonists
Infertility Treatments
Angiogenic Agents
HCG Therapy
Biomolecular Sequences

156 patents:

1. 7419999 - Gamma lactams as prostaglandin agonists and use thereof (2008-09-02),
2. 7407651 - IFN-β liquid formulations (2008-08-05),
3. 7364910 - Methods of inducing ovulation (2008-04-29),
4. 7317095 - Mutant glycoproteins (2008-01-08),
5. 7317002 - Site-specific preparation of polyethylene glycol-GRF conjugates (2008-01-08),
6. 7282352 - Homogeneity and secretion of recombinant proteins in mammalian systems (2007-10-16),
7. 7276531 - G-lactam derivatives as prostaglandin agonists (2007-10-02),
8. 7268210 - PEG-LHRH analog conjugates (2007-09-11),
9. 7259162 - Benzazole derivatives and their use as JNK modulators (2007-08-21),
10. 7258997 - Methods of increasing protein expression levels (2007-08-21),
11. 7256321 - Intracellular modulators of apoptopic cell death pathways (2007-08-14),
12. 7253199 - Azole derivatives and pharmaceutical compositions containing them (2007-08-07),
13. 7235524 - Medicaments for initiating ovulation (2007-06-26),
14. 7223732 - Compound B as an angiogenic agent in combination with human growth factors (2007-05-29),
15. 7217687 - Use of osteopontin for the treatment and/or prevention of neurologic diseases (2007-05-15),
Company Overview
Applied Research Systems Ars Holding N.V., based in Curacao, specializes in biopharmaceutical development with a focus on innovative therapeutic solutions. The company is engaged in the research and development of advanced treatments targeting various medical conditions, including neurodegenerative diseases. Its core technological expertise encompasses prostaglandin agonists, ovulation induction, glycoproteins, PEG conjugates, recombinant proteins, JNK modulators, and chemokine antagonists, positioning it as a key player in the biopharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

156 Patents

#2 in Curacao

#2 in Netherlands Antilles

#5,261 in the World

Curacao, AN
Curacao, Netherlands Antilles

Applied Research Systems Ars Holding N.v.

Forward Citations = 2,304

222 inventors:

goldMedal Scott C Chappel (12 out of 29 patents)

silverMedal Grenville Arthur Robinson (8 out of 15 patents)

bronzeMedal John W Attridge (7 out of 9 patents)

4.  Sean D McKenna (6 out of 16 patents)

5.  Fabrizio Samaritani (6 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Applied Research Systems Ars Holding N.v.. Retrieved from https://idiyas.com/company/applied-research-systems-ars-holding-n-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…